As devotees take a holy dip at Mahakumbh, the Yogi government has taken significant steps to safeguard their health.

Outset Medical (Nasdaq: OM) announced today that the FDA says it addressed all issues cited in a 2023 warning letter.

To provide medical professionals (RN, MD, Pharmacist) with the knowledge and understanding for decision making for the effective utilization of Continuous Renal Replacement Therapy (CRRT) and to allow ...

The global continuous renal replacement therapy market is set for significant expansion, with projections indicating a surge ...

The trial is assessing the efficacy and safety of the company's selective cytopheretic device (SCD) in conjunction with continuous renal replacement therapy (CRRT). The trial aims to enrol 200 adult ...

A recent meta-analysis concluded that continuous renal replacement therapy (CRRT) is not superior to intermittent renal replacement therapy (IRRT) in terms of hemodynamic control, renal recovery ...

Some clinical trials have validated a new perspective on continuous renal replacement therapy (CRRT) in combination with oXiris haemofilter to more effectively enhance endotoxins clearance and ...

Albeit negative, the results from the RENAL and ATN trials can inform clinical practice. The studies show that survival rates can be just as good when the delivery of CRRT is 19–22 ml/kg per ...

Rodman & Renshaw initiated coverage on shares of biopharmaceutical company Talphera (NASDAQ: TLPH) with a Buy rating and a price target of $4.00. The firm's analysts highlighted Talphera's focus on ...

When prolonged or further complicated, the use of CRRT might become necessary, which is one of the most resource-intensive interventions. Determining the optimal time to discontinue CRRT has been ...

Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today ...